Literature DB >> 8547652

Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain.

T Tsujimura1, M Morimoto, K Hashimoto, Y Moriyama, H Kitayama, Y Matsuzawa, Y Kitamura, Y Kanakura.   

Abstract

A peculiar point mutation results in constitutive activation of c-kit receptor tyrosine kinase (KIT) in three different tumor mast cell lines; ie, the HMC-1, P-815, and RBL-2H3. Because constitutive activation of KIT was also observed in the FMA3 mouse mastocytoma cell line, we investigated the molecular mechanism. Sequencing of the whole coding region of the c-kit showed that the point mutation found in HMC-1, P-815, and RBL-2H3 cells was absent in FMA3 cells and that the c-kit cDNA of FMA3 cells carried an in-frame deletion of 21 base pairs (bp) encoding Thr-Gln-Leu-Pro-Tyr-Asp-His at codons 573 to 579 at the juxtamembrane domain. The FMA3-type c-kit cDNA with 21 bp deletion was introduced into the IC-2 cell line, which was derived from murine cultured mast cells. IC-2 cells were dependent on interleukin (IL)-3 and did not express KIT on the surface. In IC-2 cells introduced with the FMA3-type c-kit cDNA, KIT was constitutively phosphorylated on tyrosines and activated. Moreover, the FMA3-type KIT was dimerized without the stimulation by stem cell factor (SCF), a ligand for KIT. The spontaneously dimerized FMA3-type KIT without SCF binding was not internalized even after the activation. IC-2 cells expressing the FMA3-type KIT grew in suspension culture without IL-3 and SCF and became leukemic in nude athymic mice. The deletion of seven amino acids at the juxtamembrane domain appeared to be a new activating mutation of KIT that might be involved in neoplastic growth of mast cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8547652

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.

Authors:  M L Lux; B P Rubin; T L Biase; C J Chen; T Maclure; G Demetri; S Xiao; S Singer; C D Fletcher; J A Fletcher
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

2.  A transforming mutation enhances the activity of the c-Kit soluble tyrosine kinase domain.

Authors:  L P Lam; R Y Chow; S A Berger
Journal:  Biochem J       Date:  1999-02-15       Impact factor: 3.857

3.  SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain.

Authors:  M Kozlowski; L Larose; F Lee; D M Le; R Rottapel; K A Siminovitch
Journal:  Mol Cell Biol       Date:  1998-04       Impact factor: 4.272

4.  Balanced interactions between Lyn, the p85alpha regulatory subunit of class I(A) phosphatidylinositol-3-kinase, and SHIP are essential for mast cell growth and maturation.

Authors:  Peilin Ma; Sasidhar Vemula; Veerendra Munugalavadla; Jinbiao Chen; Emily Sims; Jovencio Borneo; Takako Kondo; Baskar Ramdas; Raghuveer Singh Mali; Shuo Li; Eri Hashino; Clifford Takemoto; Reuben Kapur
Journal:  Mol Cell Biol       Date:  2011-07-26       Impact factor: 4.272

5.  Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors.

Authors:  K Isozaki; B Terris; J Belghiti; S Schiffmann; S Hirota; J M Vanderwinden
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

6.  Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.

Authors:  B J Longley; D D Metcalfe; M Tharp; X Wang; L Tyrrell; S Z Lu; D Heitjan; Y Ma
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

7.  Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296.

Authors:  Shuji Ueda; Hirokazu Ikeda; Masao Mizuki; Jun Ishiko; Itaru Matsumura; Hirokazu Tanaka; Hirohiko Shibayama; Hiroyuki Sugahara; Emi Takai; Xian Zhang; Takashi Machii; Yuzuru Kanakura
Journal:  Int J Hematol       Date:  2002-12       Impact factor: 2.490

8.  Targeted mutations of the juxtamembrane tyrosines in the Kit receptor tyrosine kinase selectively affect multiple cell lineages.

Authors:  Yuki Kimura; Nina Jones; Michael Klüppel; Masanori Hirashima; Kazunobu Tachibana; Jason B Cohn; Jeffrey L Wrana; Tony Pawson; Alan Bernstein
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-05       Impact factor: 11.205

Review 9.  Management of resectable gastrointestinal stromal tumor.

Authors:  Umer I Chaudhry; Ronald P DeMatteo
Journal:  Hematol Oncol Clin North Am       Date:  2009-02       Impact factor: 3.722

10.  Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.

Authors:  Patrice Dubreuil; Sébastien Letard; Marco Ciufolini; Laurent Gros; Martine Humbert; Nathalie Castéran; Laurence Borge; Bérengère Hajem; Anne Lermet; Wolfgang Sippl; Edwige Voisset; Michel Arock; Christian Auclair; Phillip S Leventhal; Colin D Mansfield; Alain Moussy; Olivier Hermine
Journal:  PLoS One       Date:  2009-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.